ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
4,988.73
-0.45%
US Tech 100
16,675.60
-1.54%
Dow Jones
38,008.47
0.62%
Brent Oil
87.05
0.73%
Bitcoin
64,196.64
1.09%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Anavex Life Sciences Corporation (AVXL)

  7. Anavex Life Sciences Corporation (AVXL) News

Anavex Life Sciences Corporation

Anavex Life Sciences Corporation (AVXL)

NASDAQ
3.67
-0.13
( -3.42% )
Updated: 12:57:13
Delayed by 15 minutes

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

AVXL News

Official News Only

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 23 2024
AVXL (-3.42%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 23 2024
AVXL (-3.42%)

AVXL Discussion

View Posts
jav0033 jav0033 4 minutes ago
They burn $12M per quarter so I don’t think $142M will last more trial failures
👍️0
jav0033 jav0033 5 minutes ago
Right…
Missling has already booked his European summer break in Greece.
👍️0
Steady_T Steady_T 6 minutes ago
Power is the probability of rejecting the null hypothesis when the null hypothesis is false, that is the probability of saying there is a difference when a difference actually exists. An underpowered study does not have a sufficiently large sample size to answer the research question of interest. An overpowered study has too large a sample size and wastes resources.
https://pubmed.ncbi.nlm.nih.gov/18450060/

For those that are interested in underpowered trials.
👍️0
crescentmotor crescentmotor 9 minutes ago
I hate saying it..But this stock has become impossible to defend


In the absence of material positive news, what will prevent the shorts from driving AVXL into delisting status?
👍️0
Chemdeps Chemdeps 13 minutes ago
I'm buying at these prices...never know when they will file with EMA or a partnership is announced.
👍️ 1
kund kund 21 minutes ago
You have been telling same crap since 2015, biggest manipulator is Misleading. When ever he opens up his mouth stock goes down, yesterday's presentation was one of the best he ever did in sleep.
👍️0
Thehubby Thehubby 45 minutes ago
I hate saying it..
But this stock has become impossible to defend

Missling talks, we go down
He stays silent, we go down
👍️ 2 👎️ 1 💩 1 🤡 1
attilathehunt attilathehunt 51 minutes ago
Looks like a big buying/reloading opportunity with this collusive HF manipulative take down.

LOL!!!!

So you have decided to sell your BIG purchases in the 5.35 range...Your losses must hurt!
👍️ 2
BIOChecker4 BIOChecker4 54 minutes ago
Remember, about half the market cap is cash.
👍️ 1
Monksdream Monksdream 1 hour ago
Naked shorting is an old story to explain away a prolonged decline in price
Meanwhile, AVXL new 52 lo

👍️0
mike_dotcom mike_dotcom 1 hour ago
Hilarious that a SCAM company is accusing the market of manipulation.
👍️0
toemind toemind 1 hour ago
Anyone familiar with this list of Nasdaq companies that are suspected of being impacted by "unlawful trading activity" such as naked short selling?
Is the SEC the entity charged with addressing such illegalities (but don't)?
ToeMind

"Nunes also noted in the letter that shares of the company were on a list the Nasdaq maintains that’s “indicative of unlawful trading activity.”
“This is particularly troubling given that “naked” short selling often entails sophisticated market participants profiting at the expense of retail investors,” he said. "
https://www.cnn.com/2024/04/19/markets/trump-media-nasdaq-suspected-market-manipulation/index.html
🆖 1 💩 1
kund kund 1 hour ago
Get out, it still has some value, don't listen to WGT crowd, who pumps another garbage stock NWBO. Misleading don't have data, he is messed up all trials with his super responder design.
👍️ 1
poguemahone poguemahone 2 hours ago
Sub $300M MC now….great job, Missling.
🎯 2 🏆️ 1 👍️ 3
boi568 boi568 2 hours ago
Draft guidances can be informally governing, so long as they fall within the range of an Agency's discretion and there are no outstanding rules to the contrary. I have written a draft guidance that was applied in this circumstance, as well as a proposed regulation. Both were procedural.
👍️ 1 💩 1 🤡 1
Joseph_K Joseph_K 2 hours ago
The FDA's previous Draft Guidance for Alzheimer's (2018) can be downloaded at
https://www.fda.gov/files/drugs/published/Alzheimer%E2%80%99s-Disease---Developing-Drugs-for-Treatment-Guidance-for-Industy.pdf

The link to download the 2024 Draft Guidance can be found here:
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-alzheimers-disease-developing-drugs-treatment

The differences between the February 2018 and March 2024 drafts are actually quite subtle. By 2018, the draft guidance already recognized the problem of measuring progression of functional deterioration in early Alzheimer's; that did not begin with the 2024 draft. To understand the differences between the drafts and what the drafts portend for a review of blarcamesine would require careful parsing of one against the other and a good understanding of the FDA's "Stages" of Alzheimer's and in which of those Stages the P2b/3's subjects belong. Since the drafts don't reference any test numbers, like for ADCS-ADL or MMSE, it's hard for me to make that assessment.

Also, both drafts loudly announce Contains Nonbinding Recommendations
Draft — Not for Implementation The 2018 draft went 6 years without being "implemented" and was then replaced with a new draft. I don't know how to interpret its level of influence in the agency.
🆖 1 👍️ 1 💩 2
XenaLives XenaLives 2 hours ago
It's not a "bet" at all... It's AI manipulation by entities that can wash trade all day without penalty.

That is the way they create an illusion of selling... "smoke and mirrors" is all it is.
👍️ 3 💩 3 🙄 2 🤡 1
kund kund 3 hours ago
Misleading don't have full AD data, he is just lying. In every conference he is providing clue about his total lies on AD data. WGT crowd will lose everything with their blind trust in TGD.
👍️ 1 🙁 2
Jimbo50 Jimbo50 3 hours ago
Which means these low prices again on a risk / reward basis is a good bet
🍼 1 🏧 1
game7alcs game7alcs 3 hours ago
Hey Tred, hope you enjoyed your time off and got what you need from it.

I am starting to think that possibly this is like another we experienced and the price is starting to reflect the true value of the company. On the other hand I do agree that greed drives the world and especially the market.

It certainly is not driven by the desire to help the masses.
🍼 1 🏧 1
Jimbo50 Jimbo50 3 hours ago
Starting several trials this year !
🍼 1 🏧 1
mike_dotcom mike_dotcom 3 hours ago
Usually advanced notice is given when announcing the shareholders meeting. It sure appears that they want as few shareholders there as possible. This is one sketchy company. And that's why we sit at 4 year lows - and sinking EVERY SINGLE DAY.
👍️ 1
sumbuysumsell sumbuysumsell 3 hours ago
You may want to read this:
https://en.wikipedia.org/wiki/Conspiracy_theory
🎯 1 🏆️ 1
go avxl go avxl 3 hours ago
TBSD take your golden parachute and leave

TIME IS UP
NO MORE BS
🎯 1 🏆️ 1 💩 1 🤡 1
Kentucky123 Kentucky123 3 hours ago
In the Needham conference his pace was very slow and left little time for questions. The noble conference he had to repeat the same thing several times to make sure he had no time. No desire to answer any questions about law suits or share price.
The old black preacher said" in the bible it says it came to pass it never says it came to stay."
🎯 1 🏆️ 1 👍️ 1
frrol frrol 3 hours ago
Guess you black out when you write
👍️ 1 🤡 1
poguemahone poguemahone 3 hours ago
As clueless as Missling seems (and he seems really clueless), even he has to know that shareholders are angry.

Maybe the BOD will do their job and spare him (and us) of his leadership.
🎯 1 🏆️ 1
JKS3 JKS3 3 hours ago
We have a really smart CEO. He sold all @$5.11. Now the SP is $3 something and soon going to $2 something and $1 something. Will George and BASxxx apologize to the board members?
👍️0
frrol frrol 3 hours ago
What Missling is saying is that:
1. The fact that our ADL endpoint failed is not a big deal under the new Fed guidelines, given our other endpoint outcomes that were met
2. The EMA is comfortable enough with our results that they allowed us to apply for full approval
👍️ 1
tredenwater2 tredenwater2 3 hours ago
What are the chances that one of the “peer reviewers” is communicating to “friends” that the paper is close to completion and looks very promising? Just sayin as BP’s tentacles run deep in research grants. More than one way to cause a delay in bring a novel drug to market.
🆖 1 👍️ 1 💩 1 🙄 4
mike_dotcom mike_dotcom 3 hours ago
Still no mention of any upcoming shareholders meeting. I guess their plan is to not have any shareholders left.
👍️0
crescentmotor crescentmotor 3 hours ago
I guess you are one of those people who believe in a fully rational market for all stocks at all times.

Well, your guess is both uninformed and wrong. In this age, daily trading values are influenced by a myriad of factors including powerful hedge funds, programmed algorithms, and predominant machine trading. Accordingly, there is no logic to believing in efficient market theory at least on a daily or short-term basis. But over time, the market does set a value for stocks that reflects perceived value. Companies that have announced successful trials in AD have typically been valued in the $20 billion range (before regulatory approval) and there are multiple recent precedents reflecting that enterprise value. You may believe that the AVXL AD trial was successful and the share price should be somewhere between $100 to $500 per share pre approval. But you have a real practical problem to deal with. Your problem is that no one in the world would buy your shares right now, as I type this, at a price exceeding $3.69/share. Companies that conclude Phase III clinical trials and lose 75% of their value are perceived by the marketplace to have failed trials. There is no getting around it--reality bites.
👍️ 3
Reyeton Reyeton 3 hours ago
Missing would probably be more qualified for a CFO position at some other company not as CEO here. The only hope I see and this may be a huge stretch is Missling holding back releasing AD data until the FDA eases requirements for approval. That is my best effort for cutting this guy some slack.
👍️ 1
maverick_1 maverick_1 3 hours ago
Noble Capital Markets Virtual Healthcare Equity Conference.
Christopher U Missling, PhD, President & CEO is scheduled to present at
1:30pm ET, TRACK 2 on Thursday, April 18th, 2024.

Guess nobody liked what they heard!

I have ALWAYS gotten the LAST LAUGH even on TSLA & AAPL since Fall 2023.

DIFFERENT STROKES for DIFFERENT FOLKS
🆖 1 🐀 1 👺 1 💩 1
chrismiss_everyday chrismiss_everyday 3 hours ago
https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/submission-dates/procedural-timetables
🆖 1 💩 1
Kentucky123 Kentucky123 3 hours ago
Volume drying up. We go lower.
🎯 1 🏆️ 1 👍️ 1
mrplmer mrplmer 3 hours ago
PUBLISH THE DATA. STOP THE ARROGANCE. GO TO PLAN B.
🎯 1 🏆️ 1 🐀 1 👍️ 1 👺 1
poguemahone poguemahone 3 hours ago
EVERYTHING with this company is overdue—especially replacing DM!!
🎯 1 🏆️ 1 🐀 1 👍️ 2 👺 1 🧌 1 🪳 1
chrismiss_everyday chrismiss_everyday 3 hours ago
https://www.yahoo.com/lifestyle/signs-of-multiple-sclerosis-can-be-detected-in-blood-5-years-before-symptoms-appear-new-study-finds-heres-why-this-breakthrough-is-important-090015569.html

Early detection + early treatment = positive and prolonged life experiences.
🆖 1 💩 1
LakeshoreLeo1953 LakeshoreLeo1953 3 hours ago
It's all smoke and mirrors.

NO. It is just a different "bet" than yours which happens at this time to be FAR Superior.

Perhaps the "dry powder" storage of some could assist you in doubling down?
There may yet come an appropriate time, but it is not anytime soon....even by Missling's definition.
👍️ 1 👎️ 1 👺 2 🤡 2
sumbuysumsell sumbuysumsell 3 hours ago
An announcement for the ASM is now about 2 weeks overdue.
🎯 1 🏆️ 1 🐀 1 👍️ 1 👺 1
poguemahone poguemahone 3 hours ago
It’s hard for me to fathom how DM has a PhD in ANYTHING.

YIKES!
🎯 1 🏆️ 1 🐀 1 👍️ 3 👺 1
poguemahone poguemahone 3 hours ago
The SP lows & potential lawsuits were not mentioned in the presentation. He loves to mention how big the unmet market is for ALZ, and spent too much time emphasizing the number estimates changing from 6.7M to 6.9M recently. Okay, so the number changed by 200K. Why did he feel the need to keep emphasizing this? I just cringe when DM speaks or tries to explain anything CLEARLY.

Other than hitting the iceberg, wasn’t your voyage on the Titanic wonderful?
🎯 1 🏆️ 1 🐀 1 👍️ 2 👺 1
Kentucky123 Kentucky123 3 hours ago
Could be depending on volume. First 15 min strong. Needs to continue.
👍️0
BIOChecker4 BIOChecker4 3 hours ago
Theres a huge disconnect between what Missling says in his presentation and what the market perceives. We’ll learn the truth eventually, one way or the other. I’ll continue to hold my remaining shares but I’m not going to bottom fish. If Missling actually gets EMA approval, I’ll gladly pay $20 for a 5X upside. For now, this is still a story stock that the market does now believe in.
🎯 1 🏆️ 1 🐀 1 👍️ 2 👺 1
sumbuysumsell sumbuysumsell 3 hours ago
And down the share price goes. Swirling down the drain.
I dream of a PR with the headline "Anavex Announces Management Change". It includes many attaboy pats on the back and some inspirational quotes on how far Anavex has come. The time for detailed low budget financial management is over. He did that. Congrats. There's likely another start up that he can excel with. It's now time for new leadership to take this company to the next level. Someone with integrity perhaps.
Do you see Missling running with the big boys? or no?
🎯 1 🏆️ 1 🐀 1 👍️ 2 👺 1
bas2020 bas2020 3 hours ago
Let's see how much of the collusive short positions start covering today. Looks like a big buying/reloading opportunity with this collusive HF manipulative take down.
🆖 1 🎯 2 🏆️ 2 💩 2 🤡 1
mike_dotcom mike_dotcom 4 hours ago
A new 4 year low EVERY SINGLE DAY.
👍️0
boi568 boi568 4 hours ago
Conspiracies? Underpowered?

You have a reading problem.
🏆️ 1 👍️ 2 💩 1 🤡 1
poguemahone poguemahone 4 hours ago
“He looks bored.”

I think it’s more dire than bored—he looks (and sounds) defeated.
🎯 1 🏆️ 1 🐀 1 👍️ 1 👺 1

Your Recent History

NASDAQ
AVXL
Anavex Life Sciences
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved